Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers October 21, 2018
Pharmacy Choice - Pharmaceutical News - ADMA Files Biologics License Application For Its Third Plasma Collection Center [Algeria Press Service] - October 21, 2018

Pharmacy News Article

 12/12/17 - ADMA Files Biologics License Application For Its Third Plasma Collection Center [Algeria Press Service]

ADMA Biologics, Inc. (NASDAQ:ADMA) (ADMA or the Company), a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics for the treatment of Primary Immune Deficiency Disease (PIDD) and the prevention and treatment of certain infectious diseases, announces the filing of a Biologics License Application (BLA) for its third plasma collection center located in Kennesaw, Georgia. The facility has commenced operations, initiated collections of plasma from donors and is preparing for U.S. Food and Drug Administration (FDA) review. The regulatory process entails an on-site inspection by the FDA and a BLA review period that is approximately 12 months, suggesting potential approval of ADMAs third plasma facility by the end of 2018.

We continue to leverage our expertise in establishing and operating plasma collection centers to ensure the reliable supply of source plasma for our proprietary immunoglobulin products and development-stage candidates, said Cyndi Tolman, Vice President, Plasma Services at ADMA Bio Centers (ADMA BioCenters), a wholly-owned subsidiary of ADMA Biologics, Inc. Located near Kennesaw State University, we are excited to commence operations at our newest center to serve the local community and develop a new base of plasma donors.

This new facility is expected to increase our ability to obtain raw material source plasma internally as we plan for the growth of our commercial immunoglobulin business which include Nabi-HB and Bivigam, stated Adam Grossman, ADMAs President and Chief Executive Officer. A key strategic initiative for ADMA is to sustain and efficiently grow our vertically integrated organization, which supports our mission to improve the lives of immunocompromised patients, and positions us to create value for our stockholders.

Plasma centers provide local economies with financial resources through employment opportunities and compensation to local residents for their plasma donations. Plasma can be used for the manufacturing of a variety of live-saving and life-sustaining therapies. The new ADMA facility is over 12,000 square feet and will be the Companys third center located in Georgia. It is expected to employ up to approximately 50 staff members and support over 50 donor beds at peak capacity. Plasma donors have an opportunity to earn between $ 50 and $ 350 per month by donating at an ADMA BioCenter.

(c) APS 2017. All Rights Reserved Provided by SyndiGate Media Inc. (

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Last Chance
Oct 22: An Integrative Approach to Managing Arthritis
Oct 23: NSAIDs, Acetaminophen and Adjuvants in Pain Management
Oct 24: Mobile Applications for Pharmacists: Tools That Help Pharmacies be Successful
Oct 25: Pharmacy Law & Ethics
Oct 26: Medical Marijuana: The Basic and Clinical Pharmacology, Not The Politics
Click for entire Webinar Calendar

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Nursing Jobs
Are you a nurse looking for a job?

Check out the Nursing Job Source.

Your number one choice for nursing jobs.

Websites »
Copyright © 2018 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement